1 min read
Date: June 27th 2018
Time: 11am ET
Webinar Length: 1 hour
Speakers: Brent Kendrick, VP R&D at Elion Labs and Eugene Ma, CTO at RedShiftBio
Host: Cambridge Healthtech Institute
The R&D department at Elion Labs (a division of KBI Biopharma) is studying analytical capabilities to measure the impact of manufacturing and formulation processes on protein structure. IR and CD spectroscopies are common techniques for this application. They can be used to assess and compare the impact of process changes on protein structure, structural comparisons of drugs made by different manufacturers (e.g. biosimilars), changes in structure that can occur in stored drug formulations, and optimizing protein formulations against structural impurities.
This webinar assesses the detectability of misfolded species by Microfluidic Modulation Spectroscopy (MMS), FTIR and CD spectroscopies using a system from RedShiftBio. An IgG1 drug product, which is predominantly β-sheet, is used to assess misfold detection limits by quantitatively spiking in an α-helical structural impurity. The relative abilities of common spectral data comparison and deconvolution methods to detect misfolds will be discussed.
Learning Objectives:
KBI Biopharma : May 10, 2023 3:51:41 PM
At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains,...
3 min read
KBI Biopharma : Dec 20, 2023 9:43:15 AM
Recombinant adeno-associated viruses (AAV) are an increasingly common vector for gene therapy, with two such treatments already approved by the US...
Presentation | Host Cell Protein Analysis by Mass SpectrometryMichael J Nold, Ph.D., Mass Spectrometry Core Facility, KBI Biopharma__Originally...
